LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP lessened its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 70.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,353 shares of the medical instruments supplier's stock after selling 5,730 shares during the period. Bridgewater Associates LP's holdings in LeMaitre Vascular were worth $217,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LMAT. New York State Teachers Retirement System boosted its position in shares of LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock worth $755,000 after purchasing an additional 100 shares in the last quarter. Flputnam Investment Management Co. grew its position in LeMaitre Vascular by 3.6% during the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock valued at $269,000 after buying an additional 102 shares during the period. Norden Group LLC increased its position in LeMaitre Vascular by 4.5% in the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock worth $218,000 after buying an additional 103 shares during the last quarter. Blue Barn Wealth LLC increased its stake in shares of LeMaitre Vascular by 4.4% in the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock worth $229,000 after purchasing an additional 104 shares in the last quarter. Finally, Shaker Investments LLC OH lifted its stake in shares of LeMaitre Vascular by 0.8% during the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock valued at $1,285,000 after buying an additional 112 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LMAT. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target on the stock. Finally, Lake Street Capital upped their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $95.25.

Insider Activity at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Trading Down 0.2 %

LMAT stock traded down $0.15 during trading on Friday, reaching $91.61. The stock had a trading volume of 106,920 shares, compared to its average volume of 161,598. The stock's 50 day moving average is $86.90 and its two-hundred day moving average is $93.42. The firm has a market cap of $2.07 billion, a PE ratio of 50.06, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52 week low of $64.27 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.49. The firm had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were paid a dividend of $0.20 per share. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 0.87%. LeMaitre Vascular's dividend payout ratio is presently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.